Metrochem API Private Limited Metrochem API Private Limited

X
[{"orgOrder":0,"company":"Medicines Discovery Catapult","sponsor":"Alchemab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab Extends Partnership with Medicines Discovery Catapult to Bolster Collaborative Approach to Tackle Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Medicines Discovery Catapult

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, Alchemab and MDC will evaluate antibodies using innovative technologies, including the use of high content imaging, high resolution microscopy, spatial transcriptomics to assess endpoints using induced pluripotent stem cell derived neuronal & glial cells.

            Lead Product(s): Human Monoclonal Antibody

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alchemab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY